Lv2
110 积分 2025-07-20 加入
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
29天前
已完结
Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout
1个月前
已完结
Gout and incidence of 12 cardiovascular diseases: a case–control study including 152 663 individuals with gout and 709 981 matched controls
1个月前
已完结
Machine learning–based penetrance of genetic variants
3个月前
已完结
Deep-learning-based HER2 status assessment from multimodal breast cancer data predicts neoadjuvant therapy response
5个月前
已完结
Liver-breast communication of adipocyte-oriented exosomes drives primary mammary cancer progression
6个月前
已完结
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial
6个月前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
6个月前
已完结
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
7个月前
已完结
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
7个月前
已完结
皖公网安备34019202002308
